Keyword: Boehringer Ingelheim
Boehringer is swallowing Enleofen’s anti-IL-11 antibody platform, putting it on the hook for up to $1 billion in milestones per product.
We may be nearing the first-ever approval for a NASH drug next year, but the road to approval is not getting easier.
Boehringer Ingelheim tapped Healx to help identify new drug indications and leverage its AI to explore R&D options in neurological diseases.
Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis, to the tune of $225 million.
Boehringer has moved its pan-KRAS inhibitor into phase 1 trials, both on its own and in combination with Novartis’ MEK inhibitor Mekinist.
The series A round sets Abalos up to generate anti-tumoral virus strains and take them toward testing in humans.
Short for Machine Learning Ledger Orchestration for Drug Discovery, the three-year project from the Innovative Medicines Initiative hopes to build an AI platform capable of ingesting large libraries of proprietary information while protecting its confidentiality.
Boehringer Ingelheim shuffles board, senior management; Medtronic CEO Ishrak set to retire in 2020; Zealand appoints Dallas to CFO role.
Boehringer Ingelheim and MD Anderson Cancer Center have joined forces to create a “virtual” R&D hub so the pair can work on cancer drugs.
Boehringer Ingelheim is licensing an autotaxin inhibitor from Bridge Biotherapeutics for €45 million and promising more than €1 billion in biobucks.